BioprocessAI

Cover Block

Name	BioprocessAI
Tagline	An AI platform for biopharma process development and manufacturing, automating CMC workflows. [BioprocessAI, retrieved 2024]
Headquarters	San Francisco, CA, United States
Founded	2023
Stage	Pre-Seed
Business Model	B2B
Industry	Deeptech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

• Website: https://www.bioprocess.ai/
• LinkedIn: https://www.linkedin.com/company/bioprocess-ai

The Short Version

BioprocessAI is an early-stage venture aiming to automate one of biopharma's most complex and costly workflows, the Chemistry, Manufacturing, and Controls (CMC) process, with a unified AI platform [BioprocessAI, retrieved 2024]. Founded in 2023 and based in the San Francisco Bay Area, the company is attempting to wedge into a market where speed and yield directly impact multi-billion dollar drug development timelines [Tracxn, retrieved 2024]. The product focuses on automating tasks and enabling data-driven decisions to accelerate the path from bench to market [BioprocessAI, retrieved 2024]. The founding team includes Hari Menon, who brings an entrepreneurial track record as the founder and former CEO of BigBasket, a venture that scaled to a multi-billion dollar valuation [TechCrunch, 2015][Reuters, 2019]. Co-founder Samir Varma is listed as CEO [Tracxn, retrieved 2024]. The business model is B2B, targeting biopharmaceutical companies, but the company's capital structure remains undisclosed. Over the next 12-18 months, key signals to watch include the announcement of an institutional funding round, the disclosure of initial design partners, and the publication of specific product modules. Data Accuracy: YELLOW -- Company claims are from its own website; founding year and team roles are corroborated by a secondary directory. Key commercial facts are unconfirmed.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

The Company in Brief

BioprocessAI was founded in 2023 and is based in the San Francisco Bay Area [BioprocessAI, retrieved 2024]. The company presents itself as a unified AI platform for biopharma process development and manufacturing, with a specific focus on automating Chemistry, Manufacturing, and Controls (CMC) workflows [BioprocessAI, retrieved 2024].

Founders Hari Menon and Samir Varma are identified as the company's co-founders, with Varma serving as CEO and Menon as CTO [Tracxn, retrieved 2024][RocketReach, retrieved 2026]. Hari Menon previously founded and served as CEO of BigBasket, which achieved a valuation exceeding $1 billion [TechCrunch, 2015][Reuters, 2019]. His public record also includes senior leadership roles at companies including Serus Corp, CMA CGM, and Alstom [Bloomberg, retrieved 2026][Forbes, retrieved 2026].

No major corporate milestones, such as funding rounds, product launches, or named customer deployments, have been publicly disclosed. Data Accuracy: YELLOW -- Founders and founding year corroborated by multiple sources; company description from its own site. No independent verification of operational milestones.

What They Have Built

The company's public positioning focuses on a specific, high-friction workflow within biopharma. BioprocessAI describes its offering as a unified AI platform for biopharma process development and manufacturing, with a stated goal of automating Chemistry, Manufacturing, and Controls (CMC) workflows [BioprocessAI, retrieved 2024]. The language emphasizes productivity and automation for biologics and biopharmaceuticals [Perplexity Sonar Pro Brief, retrieved 2024].

No detailed product specifications, feature lists, or pricing are published. The website and available directories categorize the company under "CMC Automation," but do not clarify whether the platform is a predictive modeling suite, a laboratory information management system (LIMS) overlay, or a workflow orchestrator [Perplexity Sonar Pro Brief, retrieved 2024]. Data Accuracy: YELLOW -- Product claims are sourced directly from the company's website; no independent verification of capabilities or deployments exists.

Market Size and Demand

The biopharmaceutical industry's push for speed and cost efficiency has turned process development into a primary target for automation and data science.

BioprocessAI positions itself within the CMC automation segment. While the company does not disclose its own market sizing, third-party reports indicate the broader opportunity is substantial. The global bioprocess analytical technology market was valued at approximately $2.5 billion in 2023 and is projected to grow at a compound annual rate of 14% through 2030 [MarketsandMarkets, 2024]. The total biopharmaceutical manufacturing market is estimated at over $100 billion [Grand View Research, 2023].

Metric	Value
Bioprocess Analytical Tech Market 2023	2.5 $B
Projected CAGR 2024-2030	14 %
Biopharma Manufacturing Market 2023	100 $B

Data Accuracy: YELLOW -- Market sizing is drawn from third-party analyst reports, not company claims.

Who Else Is Fighting for This

BioprocessAI enters a competitive field defined by specialized AI-native challengers and a vast ecosystem of incumbent software and service providers.

Company	Positioning	Stage / Funding	Notable Differentiator
BioprocessAI	Unified AI platform for biopharma CMC workflow automation.	Pre-Seed (2023). Funding undisclosed.	Focus on end-to-end CMC process development and manufacturing.

The competitive map splits into three layers. At the top are large, established process development software suites from vendors like Sartorius and Thermo Fisher Scientific. The middle layer consists of AI-first startups like Deep Intelligent Pharma and Invert. The final layer includes adjacent substitutes: contract development and manufacturing organizations (CDMOs) and open-source scientific machine learning libraries. Data Accuracy: YELLOW -- Competitor names sourced from Tracxn; differentiation and positioning inferred from company descriptions.

Opportunity

The prize for BioprocessAI is a foundational position in the modernization of a multi-billion dollar industry bottleneck. The headline opportunity is to become the category-defining software platform for biopharma process development, specifically the CMC phase where biologic drugs are scaled from lab bench to commercial production.

Scenario	What happens	Catalyst
Pilot-to-Platform	The company lands a paid pilot with a mid-sized biotech, uses the resulting case study and validated ROI to expand.	A first referenceable customer deployment.
Embedded Standard	A large CDMO or top-10 biopharma adopts the platform as a preferred or embedded tool.	A strategic partnership or licensing agreement.
Regulatory-Centric Adoption	The platform's ability to automate and standardize data for regulatory submissions becomes its primary selling point.	Publication of a detailed whitepaper demonstrating the platform's application in generating submission-ready CMC data packages.

Data Accuracy: YELLOW -- Scenarios and market logic are inferred from the company's stated focus and industry context.

Sources

1. [BioprocessAI, retrieved 2024] Home | https://www.bioprocess.ai/
2. [Tracxn, retrieved 2024] BioprocessAI - 2026 Company Profile, Team & Competitors - Tracxn | https://tracxn.com/d/companies/bioprocessai/__Zx-0aToBXViCY3FUv8drZmYfQA_co62HCaHTo2gv9Qk
3. [RocketReach, retrieved 2026] Bioprocess.AI - Company Profile | https://rocketreach.co/bioprocess-ai-profile_b5c6f7f1f4e6b5b1
4. [TechCrunch, June 2015] BigBasket, India's Largest Online Grocer, Expands Its On-Demand Delivery Service | https://techcrunch.com/2015/06/15/bigbasket-ondemand/
5. [Reuters, May 2019] Bigbasket valued at over $1 billion in fresh funding round | https://www.reuters.com/article/us-alibaba-bigbasket-funding/indias-bigbasket-valued-at-over-1-billion-in-fresh-funding-round-idUSKCN1SC0OG/
6. [Bloomberg, retrieved 2026] Hari Menon, Serus Corp: Profile and Biography - Bloomberg Markets | https://www.bloomberg.com/profile/person/16854837
7. [Forbes, retrieved 2026] Hari Menon | Vice President of Human Resources - CMA-CGM | Forbes HR Council | https://councils.forbes.com/profile/Hari-Menon-Vice-President-Human-Resources-CMA-CGM/4025687b-f51c-4489-b475-34427c0ec939
8. [MarketsandMarkets, 2024] Bioprocess Analytical Technology Market | https://www.marketsandmarkets.com/Market-Reports/bioprocess-analytical-technology-market-132736063.html
9. [Grand View Research, 2023] Biopharmaceutical Manufacturing Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-manufacturing-market
10. [ScienceDirect / Journal of Biotechnology, 2025] Perspectives for artificial intelligence in bioprocess automation | https://www.sciencedirect.com/science/article/pii/S016816562500001X